
Passage BIO, Inc. — Investor Relations & Filings
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| FORM 8-K | 2026-05-26 | English | |
| 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | |
| 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | |
| ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 47845684 | 8-K | 2026-05-27 | English | ||
| 47059730 | FORM 8-K | 2026-05-26 | English | ||
| 45232728 | 10-Q - Passage BIO, Inc. (0001787297) (Filer) | 2026-05-12 | English | ||
| 37959866 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-28 | English | ||
| 34690715 | 8-K - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-20 | English | ||
| 33703026 | ARS - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 33703035 | DEF 14A - Passage BIO, Inc. (0001787297) (Filer) | 2026-04-07 | English | ||
| 32979094 | 4 - Passage BIO, Inc. (0001787297) (Issuer) | 2026-03-18 | English | ||
| 32898268 | 10-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 32898267 | 8-K - PASSAGE BIO, INC. (0001787297) (Filer) | 2026-03-03 | English | ||
| 13203760 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203761 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13203762 | FORM 8-K | 2026-01-12 | English | ||
| 13203764 | Regulatory Filings 2026 | 2026-01-09 | English | ||
|
2025
1 filing
| |||||
| 13203763 | Director's Dealing 2025 | 2025-12-29 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
COGSTATE LTD
Develops digital brain health assessments for clinical tria…
|
CGS | AU | Professional, scientific and te… |
|
Combigene AB
A gene therapy company focused on neurological disorders an…
|
COMBI | SE | Professional, scientific and te… |
|
Compugen Ltd.
A clinical-stage company developing cancer immunotherapies …
|
CGEN | IL | Professional, scientific and te… |
|
COMPUGEN LTD
A clinical-stage company using AI to discover cancer immuno…
|
CGEN | US | Professional, scientific and te… |
|
Core One Labs Inc.
Biotechnology research and technology developing and commer…
|
COOL | CA | Professional, scientific and te… |
|
CORESTEMCHEMON Inc.
Develops stem cell therapies and provides non-clinical CRO …
|
166480 | KR | Professional, scientific and te… |
|
CRONEX.CO.,LTD
A CRO supplying biological species and bio-tissue materials…
|
215570 | KR | Professional, scientific and te… |
|
C&R Research Inc.
A full-service CRO providing clinical research for pharma a…
|
359090 | KR | Professional, scientific and te… |
|
CSG Digital Power Grid Research Institute Co.,Ltd.
Develops AI, IoT, and digital grid technologies for power s…
|
301638 | CN | Professional, scientific and te… |
|
CTC - CENTRO DE TECNOLOGIA CANAVIEIRA S.A.
Develops advanced sugarcane varieties to optimize agricultu…
|
— | BR | Professional, scientific and te… |
Passage BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34849/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34849 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34849 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34849 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34849}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Passage BIO, Inc. (id: 34849)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.